Skip to main navigation
  • Contact Us
  • Global
    • International
    • Canada
    • France
    • Germany
    • Italy
    • Japan
    • Netherlands
    • Spain
Amicus Therapeutics
  • About Amicus
    • About Amicus
    • Chairman’s Welcome
    • Leadership
    • Belief Statement
    • Contact Us
    • Message from BIO
  • Patient Advocacy
    • Patient Advocacy
    • Disease Information
    • Rare Stories
    • Patient Advisory Boards
    • Corporate Giving
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Programs & Pipeline
    • Our Pipeline
    • Fabry Disease
    • Pompe Disease
    • Batten Disease
    • Additional Preclinical Programs
    • Clinical Trials
    • Platform Technologies
    • Journal Articles
    • Publications & Posters
  • Product
    • Product
    • Galafold®
    • Amicus Assist™
  • Responsibility
    • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Investors & Media
    • Investor Relations
    • Senior Management Team
    • Board of Directors
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports and Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Contact Us
    • Sign Up for Email Alerts
  • Careers
    • Careers
    • Overview
    • Search

Investors

Press Releases

Press Releases

September 1, 2023
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
August 29, 2023
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
August 21, 2023
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
August 15, 2023
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
August 8, 2023
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
July 31, 2023
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
June 27, 2023
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
May 10, 2023
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
May 2, 2023
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
May 1, 2023
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
  • About Amicus
    • Chairman’s Welcome
    • Leadership
    • Belief Statement
    • Contact Us
    • Message from BIO
  • Patient Advocacy
    • Disease Information
    • Rare Stories
    • Patient Advisory Boards
    • Corporate Giving
    • Resources
    • Expanded Access
  • Programs & Pipeline
    • Pipeline
    • Our Programs
    • Clinical Trials
    • Platform Technologies
    • Publications & Posters
    • Journal Articles
  • Product
    • Overview
    • Amicus Assist™
  • Responsibility
    • Ethics & Compliance
    • Global Medical Affairs
    • Corporate Giving
    • Healing Beyond Disease
    • ESG Report
  • Investors & Media
    • Corporate Governance
    • Press Releases
    • Events & Presentations
    • Annual Reports & Proxies
    • SEC Filings
    • Stock Performance
    • Investor FAQs
    • Featured Coverage
  • Careers
    • Overview
    • Search
  • Social Media
    • Twitter
    • YouTube
    • LinkedIn
Copyright © 2023 Amicus Therapeutics. All rights reserved. NP-AT-ALL-00011119
  • Cookies Statement
  • Terms of Use
  • Privacy Notice
  • Privacy Shield Policy

The site you are about to enter is intended for US healthcare professionals.

Please confirm you are a US healthcare professional.

I am a US healthcare professional I am not a US healthcare professional